Tripeptidyl peptidase I (TTP-I), also known as CLN2, a member of the family of serine-carboxyl proteinases (S53), plays a crucial role in lysosomal protein degradation and a deficiency in this enzyme leads to fatal neurodegenerative disease. Recombinant human TPP-I and its mutants were analyzed in order to clarify the biochemical role of TPP-I and its mechanism of activity. Ser280, Glu77, and Asp81 were identified as the catalytic residues based on mutational analyses, inhibition studies, and sequence similarities with other family members. TPP-I hydrolyzed most effectively the peptide Ala-Arg-Phe*Nph-Arg-Leu (*, cleavage site) (k cat /K m = 2.94 µM -1 ·s -1 ). The k cat /K m value for this substrate was 40 times higher than that for Ala-Ala-Phe-MCA. Coupled with other data, these results strongly suggest that the substrate-binding cleft of TPP-I is composed of only six subsites (S 3 -S 3 ′). TPP-I prefers bulky and hydrophobic amino acid residues at the P 1 position and Ala, Arg, or Asp at the P 2 position. Hydrophilic interactions at the S 2 subsite are necessary for TPP-I, and this feature is unique among serine-carboxyl proteinases. TPP-I might have evolved from an ancestral gene in order to cleave, in cooperation with cathepsins, useless proteins in the lysosomal compartment.
Neuronal ceroid lipofuscinoses (NCLs) are the most common inherited progressive neurodegenerative disorders of childhood (1) (2) (3) , manifested by ceroid and lipofuscinlike autofluorescent deposits accumulating in different tissues. These diseases are characterized by vision loss, progressive neurodegeneration (seizures, ataxia, and psychomotor deterioration), and premature death (2) . Classical late-infantile neuronal ceroid lipofuscinosis (LINCL), a progressive and fatal neurodegenerative disease of childhood, is caused by a variety of mutations in the CLN2 gene (1) (2) (3) (4) .
The CLN2 gene product (CLN2) was identified as a 46-kDa glycoprotein exhibiting sequence similarity with bacterial pepstatin-insensitive carboxyl proteinases (4) . CLN2 shares 22% identity with sedolisin (Pseudomonas serine-carboxyl proteinase) (5), 29% identity with sedolisin-B (Xanthomonas serine-carboxyl proteinase) (6) , 35% identity with kumamolisin (kumamolysin) (7) , and 34% identity with kumamolisin-B (proteinase J-4) (8, 9) . CLN2 is involved in lysosomal protein degradation (10) , and its deficiency results in the accumulation of subunit c of the mitochondorial ATP synthase complex (F 0 F 1 -ATPase) in lysosomal vesicles (11, 12) . Subunit c is a major component of an autofluorescent material, ceroid-lipofuscin, in lysosomal storage bodies (11) .
CLN2 was identified in 1999 as tripeptidyl peptidase I [EC 3.4.14.9], based mainly on analysis of its sequence (13, 14) . A typical Gly-Thr-Ser motif, present in the region surrounding the catalytic serine in subtilisin-like serine peptidases, is also conserved in TPP-I/CLN2. However, no histidine or lysine residue, potentially acting as a general base, was found in the sequences of CLN2 or related bacterial sedolisins. We have previously reported that Asp170 and Asp328 in the sedolisin molecule appear to be essential for the catalytic function of this enzyme (15) . On the other hand, it was reported that Ser280 in TPP-I is crucial for its catalytic function, based on mutational analysis and chemical modification (16) . Thus, at that stage, the catalytic mechanism of these enzymes was still ambiguous. However, in 2001, we solved the crystal structure of sedolisin at high resolution and defined a novel family of serine-carboxyl peptidases (sedolisins, MEROPS S53) (17) . A unique catalytic triad, Ser287-Glu80-Asp84, was shown to be responsible for the catalytic function, and it was postulated that Asp170 is involved in the formation of an oxyanion hole (these residues correspond to Ser280-Glu77-Asp81 and Asp165 in TPP-I, respectively) (9, (17) (18) (19) (20) . In addition, Asp328
J. Biochem.
(corresponding to Asp322 in TPP-I) was found to be involved in the creation of an essential Ca 2+ binding site (17) . The catalytic mechanism of this family was postulated to utilize glutamate as a general base, abstracting a proton from the serine that acts as a nucleophile.
TPP-I is a unique enzyme having both tripeptidyl peptidase activity for tridecapeptides and endopeptidase activity for decapeptides (21) . The gene encoding TPP-I has been identified in a number of mammals, and the protein has been purified from a variety of sources, including human and mouse tissues (21) (22) (23) (24) (25) (26) (27) . TPP-I is widely distributed among such higher organisms as mammals and fish, and may play important roles in their life cycles (9) .
TPP-I sequentially removes tripeptides from the Nterminus of peptide hormones such as angiotensin II, glucagons, and substance P (21, 27, 28) . The subsite structure of TPP-I has not been analyzed yet. The enzyme activity is strongly inhibited by Ala-Ala-Phe-chloromethylketone (27) . The hexahistidine-tagged TPP-I was completely inhibited by incubation for 70 min with 2 mM DFP at 25°C and pH 4.5 (16) . In contrast, rat spleen TPP-I was not inhibited by incubation with 10 mM DFP and 1 mM PMSF for 10 min at 37°C and pH 4.0 (21) . Sedolisin and kumamolisin are also insensitive to PMSF (29, 30) . Thus, the inhibitory activities of such serine-modifying regents for sedolisins are still ambiguous.
In this study, human TPP-I and its mutants were expressed in silkworm pupae and purified to a homogeneous state. The role of the putative catalytic residues of TPP-I was investigated using purified enzymes, and, in addition, the substrate specificity of TPP-I was analyzed by using synthetic peptide substrates.
EXPERIMENTAL PROCEDURES
Materials-pCLN2#17-GemT, including human CLN2 cDNA cloned by PCR, was a generous gift from Dr. J. Ezaki (Juntendo University, Tokyo, Japan). Restriction enzymes, calf intestine alkaline phosphatase, KOD-Dash polymerase, and kits for molecular biology were purchased from TOYOBO Co. (Osaka, Japan). PRISM dye terminator cycle sequencing kits were obtained from Perkin-Elmer (Chiba, Japan). RNase, AEBSF [4-(2-aminoethyl)benzene sulfonyl fluoride], Ala-Ala-Phe-chloromethylketone (AAF-CMK), and Ala-Ala-Phe-7-amido-4-methylcoumarin (Ala-Ala-Phe-MCA) were from Sigma (St. Louis, MO). Glycopeptidase F was obtained from Takara Bio (Kyoto, Japan). The BCA Protein Assay Reagent kit and Geneclean II kit were from Pierce (Rockford, IL) and Funakoshi (Tokyo, Japan), respectively. Oligonucleotides for cloning and sequencing were purchased from Kiko-Tech (Osaka, Japan). An antibody against CLN2 prepared using the carboxyl terminal fragment of human CLN2 (amino acid residues from Glu207 to Val323) (11) , was a generous gift from Dr. E. Kominami and Dr. J. Ezaki (Juntendo University, Tokyo, Japan). CM-Sepharose, DEAE-Sepharose, Octyl-Sepharose, Superdex-200, and Mono-S were from Amersham Pharmacia Biotech. (Buckinghamshire, UK). Ac-IAF-CHO (N-acetylisoleucyl-alanyl-phenylalaninal) and Ac-IPF-CHO (Nacetyl-isoleucyl-prolyl-phenylalaninal) were kindly synthesized by Dr. K. Uchida (Teikyo University, Utsunomiya, Japan). Acetylpepstatin (N-acetyl-valyl-valyl-AHMHA-alanyl-AHMHA; AHMHA, 4-amino-3-hydroxy-6-methylheptanoic acid) and tyrostatin (N-isovaleryltyrosyl-leucyl-tyrosinal) were purified in our laboratory from microbial sources (31, 32 DNA manipulation-Plasmids were isolated by alkaline lysis and polyethylene glycol 6,000 precipitation (34) . Competent cells for transformation were prepared by the method of Hanahan with a slight modification (35) . E. coli JM109 cells were cultivated for 44 h at 18°C for high efficiency of transformation. The transformation buffer used here comprised 10 mM PIPES buffer, pH 6.7, containing 15 mM CaCl 2 , 0.25 M KCl, and 55 mM MnCl 2 . Nucleotide sequences were determined using a PRISM dye terminator cycle sequencing kit and an Applied Biosystems DNA sequencer model 373A. The reaction mixture was loaded on a 5.25% denaturing polyacrylamide gel. The nucleotide sequence was analyzed using the DNASIS software programs (Hitachi) for the prediction of an amino acid sequence.
Peptide Substrates-Lys-Pro-Ile(P 3 )-Glu(P 2 )-Phe*NphArg(P 2 ′)-Leu (*; cleavage site, Nph; p-nitrophenylalanine), with substitutions at the P 3 (36, 37) . Ala-Ala-Ala-Phe*Nph-Arg-Leu and Ala-Ala-Phe*NphArg-Leu were also used. In addition, combinatorial peptide substrates, Ala-Xaa-(Tyr/Nle/Leu/Trp/Phe)*NphXaa-Leu (Xaa; 19 amino acid residues excluding Cys) were used to study the preference at the P 1 position. LysPro-Xaa-Glu-P 1 *Nph-Xaa-Leu were used to study preference at the P 1 position of sedolisin and kumamolisin (Xaa and P 1 ; 19 amino acid residues excluding Cys and Met, plus norleucine). The cleavage of the substrate between Phe (or P 1 ) and Nph was monitored at 37°C and pH 4.0 in 0.1 M sodium acetate buffer. The decrease in absorbance at 300 nm was monitored using a Beckman DU-7400 spectrophotometer.
Expression of Recombinant Enzyme in Silkworm PupaepCLN2#17-GemT was digested with XhoI and SalI, and the resultant fragment was cloned into the SalI-digested pTZ. The plasmid was digested with BamHI and EcoRV, and the resultant fragment was cloned into the BglII and SmaI-digested plasmid pYNG. The constructed vector, pYNG-CLN2, was expressed in pupae using a baculovirus system (33) .
Purification of the Recombinant TPP-I-Five virusinfected pupae were homogenized with 20 mM Tris-HCl buffer, pH 8.0, containing 10% glycerol, 0.1 M NaCl, 1 mM EDTA, and 10 mM benzamidine. Triton X-100 was added to this preparation to a final concentration of 1%. After removal of insoluble materials by centrifugation (10,000 × g, 1 h, 4°C), a small amount of thiourea was added to the supernatant. This final preparation (pupal hemolymph) was stored at -30°C until use. The pupal hemolymph was dialyzed against 10 liters of 20 mM sodium acetate buffer, pH 4.0, containing 50 mM NaCl and 0.1% Triton X-100 (buffer A). The sample was loaded onto a column of CM-Sepharose (φ 2 × 25 cm) equilibrated with buffer A. The adsorbed enzyme was eluted with a linear gradient of 0.05 to 0.8 M NaCl in buffer A. The active fractions were mixed with 100 ml of octylSepharose equilibrated with 20 mM sodium acetate buffer, pH 4.0, containing 0.4 M NaCl and 0.1% Triton X-100 (buffer B). The resin was packed into a glass column (φ 2 × 35 cm). The adsorbed enzyme was eluted with a linear gradient of 0 to 2% Triton X-100. The active fractions were dialyzed against 2 liters of buffer A. The sample was loaded onto a column of Mono-S (φ 0.5 × 5 cm) equilibrated with buffer A. The adsorbed enzyme was eluted with a linear gradient of 0.05 to 0.8 M NaCl in buffer A (flow rate: 0.5 ml/min). Active fractions were pooled and stored at -80°C until use. All procedures were carried out at 4°C, except for FPLC (room temperature) on the Mono-S column.
Kinetic Assays-Cleavage of each substrate between Phe and Nph was monitored at 37°C in 0.1 M sodium acetate buffer, pH 4.0. The decrease in absorbance at 300 nm was monitored using a Beckman DU-7400 Diode Array Spectrophotometer. For each kinetic assay, two tubes (tube 1: different concentration of substrate, tube 2: enzyme) were warmed for 5 min at 37°C. After the contents of the two tubes were mixed, the linear rate of absorbance change was measured to give the initial velocity. Kinetics constants were calculated using Lineweaver-Burk plots, with at least five initial substrate concentrations (15-100 µM).
Tripeptidyl Peptidase Activity and Protein Concentration-Tripeptidyl peptidase activity was assayed as described by Ezaki et al. with slight modification (21) . Reaction mixtures comprised 0.1 µM Ala-Ala-Phe-MCA, 0.1 M sodium acetate buffer, pH 4.0, and the enzyme, in a final volume of 0.1 ml. After incubation at 37°C for 10 min, the reaction was terminated by adding 0.1 ml of 10% SDS and 2 ml of 0.1 M Tris-HCl, pH 9.0. One unit of activity was defined as the amount of enzyme that gives one unit of fluorescence intensity for 10 min (excitation, 380 nm; emission, 460 nm). Protein concentration was estimated with a BCA Protein Assay Reagent kit using bovine serum albumin as a standard. Each inhibitor was incubated with the enzyme at 37°C for 10 min, and then the remaining activity was assayed using Ala-Ala-Phe-MCA as a substrate.
Homogeneity-Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out according to the method of Laemmli in 12.5% polyacrylamide gels in 0.375 M Tris-HCl buffer, pH 8.8, containing 7.3% acrylamide, 0.2% N,N′-methylenebisacrylamide, and 0.1% SDS (38) . Electrophoresis was carried out at a constant current of 20 mA at room temperature. Gels were stained with Coomassie Brilliant Blue R-250 in order to detect protein bands. Western blot analysis was carried out according to the method of Towbin et al., using a mouse anti-CLN2 antibody and alkaline phosphate-conjugated mouse IgG antibody (39) .
Deglycosylation with Glycopeptidase F-The reaction mixture comprised purified enzyme (10 µg), 0.1 M 2-mercaptoethanol, 0.5% SDS, and 0.5 M Tris-HCl, pH 8.6, in a final volume of 5 µl. After boiling for 3 min, 5 µl of 5% Nonidet P-40 and 13 µl of distilled water were added. Glycopeptidase F was added, and the sample was incubated at 37°C for 17 h. Removal of oligosaccharide chains was analyzed by SDS-polyacrylamide gel electrophoresis.
Construction of TPP-I Mutants-Polymerase chain reactions were carried out in order to introduce the E77A (GAG to GCG), D81A (GAT to GCT), D165A (GAC to GCC), S280A (TCG to GCG), and D322A (GAT to GCT) mutations into the human TPP-I cDNA sequence. Two outside primers covering either the 5′-or 3′-coding regions and complementary primers containing nucleotide changes were used for the first reaction. The reaction products were each purified using a Geneclean II kit and mixed with the outside primers. The products obtained by the second PCR were subcloned into pUC19 and the insert fragments were sequenced to confirm the presence of the desired mutations. pUC-E77A and pUC-D81A were digested with BstII and XbaI, and each fragment was inserted into the BstII and XbaI-digested pCLN2#17-GemT. pUC-D81A was digested with BstEII and BspEI, and the fragment was inserted into the BstEII and BspEI-digested pCLN2#17-GemT. pUC-D165A, pUC-S280A, and pUC-D322A were digested with SalI and XbaI, and the resultant fragments were inserted into the SalI and XbaI-digested pCLN2#17-GemT.
Purification of Muteins S280A and E77A-Muteins S280A and E77A were expressed in pupae. Each hemolymph (50 ml) was dialyzed against 1 liter of buffer A. As described in the section "Purification of the recombinant TPP-I," each mutant was purified by a series of CMSepharose, Octyl-Sepharose and Mono-S chromatographies. For further purification, each of the final preparations obtained here was concentrated and loaded onto a column of Superdex 200 (φ 1.0 × 30 cm) equilibrated with buffer A. Purified muteins, S280A and E77A, were stored at -80°C until use. All procedures were performed at 4°C, except for FPLC on Mono-S and Superdex 200 (room temperature). During purification, each mutein was monitored by Western blot analysis.
RESULTS

Purification and Properties of the Recombinant Enzyme-
A recombinant CPd virus harboring pYNG-CLN2 was introduced into silkworm pupae. The infected pupae produced an immunoreactive protein. All the wild-type and mutant TPP-I proteins were synthesized as 66-kDa inactive precursors consisting of a 195 residue prepro-peptide and 368 residue mature enzyme. Most of the precursor proteins were converted to a 46-kDa form by post-translational proteolysis. It has been previously reported that, in vivo, the precursor of TPP-I is converted to the 46-kDa mature form by auto-activation in an intramolecular fashion under acidic conditions (4, 16, (40) (41) (42) , and that, in vitro, the conversion is most likely due to the activity of endogenous proteinases in host cells during expression (41) . We observed similar behavior during the expression
of TPP-I in silkworm pupae, since the purification procedure yielded the mature enzyme. As shown in Table 1 , the purified wild-type TPP-I (4.6 mg), with a specific activity of 7,500 units/mg, was obtained from the pupal hemolymph. The specific activity corresponds to 228 nmol/min/mg according to the method of Ezaki, J. et al., which coincides well with that of purified rat spleen TPP-I (21). The enzyme showed a single protein band (46 kDa) on SDS-PAGE (Fig. 1, line 2 ). After incubation with glycopeptidase F at 37°C for 17 h, the enzyme was converted to a 40-kDa protein (Fig. 1, line 1) . Some properties of the recombinant enzyme were examined using Ala-Ala-Phe-MCA as a substrate. We found that the enzymatic activity was stable in a pH range from 2.5 to 5.0, with an optimum pH of 4.0; activity was lost above pH 7.
Inhibition Studies-The inhibitory activities of selected inhibitors of TPP-I are summarized in Table 2 . TPP-I was strongly inhibited by 0.1 mM AAF-CMK (26, 27) . The enzyme inactivated by AAF-CMK was dialyzed twice against 100 volumes of 25 mM acetate buffer, pH 4.0, for 2 h at 4°C, but the treated enzyme did not recover its original activity. In contrast, sedolisin was not inhibited under the same conditions, or even after the inhibitor concentration was raised to 2 mM. TPP-I was also inhibited by 1 mM Ac-IAF-CHO, but was insensitive to acetylpepstatin and tyrostatin. In addition, TPP-I was not inhibited by AEBSF, even at a concentration of 20 mM. A similar lack of inhibition (at an inhibitor concentration of 10 mM) was also observed in our studies of sedolisin and kumamolisin (unpublished data).
Mutational Analysis-In order to identify the catalytic residues of TPP-I, we selected Glu77, Asp81, Asp165, and Ser280 for mutagenesis, based on their absolute sequence conservation among sedolisins (9) . As mentioned above, recombinant TPP-I (wild-type) was produced in silkworm pupae mainly as the 46-kDa mature form (Fig. 2, lane 1) that showed normal tripeptidyl peptidase activity. The E77A and S280A mutant forms were expressed in the same manner as the wild-type enzyme (Fig. 2, lanes 2 and 5) , but neither crude mutein showed enzymatic activity, even after acid activation. The D81A and D165A mutant forms were not produced in a soluble form (Fig. 2, lanes 3 and 4) , although D165A was found in the insoluble material (data not shown). In contrast, the wild-type and D165A enzymes were expressed as soluble precursors in Sf-9 insect cells, although D165A was completely inactive (data not shown). It must be stressed that silkworm pupae (Bombyx mori) and Sf-9 cells (Spodoptera frugiperda) are very different types of host cells and that the culture conditions of Sf-9 cells might be suitable for normal folding of the D165A mutein. No D81A mutein was observed even in the insoluble material (data not shown). This lack of expression might be due to endogenous problems in the silkworm expression system.
Muteins S280A and E77A were purified from pupal hemolymphs as described under "EXPERIMENTAL PROCE-DURES." As shown in Fig. 3 , each enzyme showed a single band at around 46 kDa. The purified S280A could not cleave the substrate Ala-Arg-Phe*Nph-Arg-Leu, whereas the purified E77A showed very low, but measurable activity. Kinetic parameters of E77A for Ala-ArgPhe*Nph-Arg-Leu were k cat = 0.0124 s -1 , K m = 123 µM, and k cat /K m = 0.0001 µM -1 ·s -1 . The k cat /K m value was four orders of magnitude lower than that of wild-type TPP-I The Sizes of Subsites-The substrate specificity of TPP-I was investigated using the octapeptides described in "MATERIALS AND METHODS," based on the parent substrate Lys-Pro-Ile-Glu-Phe*Nph-Arg-Leu (Nph, p-nitrophenylalanine; *, cleavage site). TPP-I hydrolyzed the S 5 -S 3 ′ substrate Lys-Pro-Ile-Ala-Phe*Nph-Arg-Leu most effectively among them, but its k cat /K m value was only 0.0024 µM -1 ·s -1 (k cat = 0.68 s -1 ; K m = 288 µM). TPP-I showed higher activities against the S 4 -S 3 ′ substrate AlaAla-Ala-Phe*Nph-Arg-Leu and the S 3 -S 3 ′ substrate AlaAla-Phe*Nph-Arg-Leu. k cat /K m values of TPP-I for the hepta-and hexapeptide substrates were 0.15 and 2.33 µM -1 ·s -1 , respectively. These values are 63 and 970 times higher than that for the octapeptide substrate described above. Tripeptidyl peptidase activities of bacterial homologues such as sedolisin, sedolisin-B, kumamolisin, and kumamolisin-B for Ala-Ala-Phe-MCA were less than 1% that of TPP-I.
Substrate Specificity-(1) Effects of the P 1 residue of the substrate: The P 1 preference of TPP-I was studied using combinatorial peptide substrates Ala-Xaa-(Tyr/ Nle/Leu/Trp/Phe)*Nph-Xaa-Leu. TPP-I cleaved all of the P 1 -substituted substrates (Table 3) . TPP-I preferred the following amino acid residues at the P 1 position: Phe (100%), Nle (97%), Tyr (82%), Leu (78%), and Trp (67%). By contrast, sedolisin preferentially cleaves peptides having a Glu or Asp at the P 1 position, whereas kumamolisin prefers Arg at the P 1 position (Table 3) . Both enzymes also hydrolyzed P 1 -Phe or P 1 -Tyr derivatives.
(2) Effects of the P 2 residue of the substrate: TPP-I preferentially cleaved peptides having an Arg, Ala or Asp at the P 2 position (Table 4 ). The best P 2 replacement was arginine. The k cat /K m value was 2.94 µM -1 ·s -1 , which was the highest value among the substrates tested in this study. This value is 40 times higher than that for AlaAla-Phe-MCA (k cat /K m = 0.068 µM -1 ·s -1 ), the general assay substrate for TPP-I (21). Replacement of Arg by Ser or His decreased the k cat /K m value in this order. (3) Effects of the P 3 residue of the substrate: TPP-I preferentially cleaved peptides with an Ala residue at the P 3 position (Table 4 ). Replacement of Ala by Asp, His, Arg, or Ser significantly decreased the k cat /K m value in this order. The specificity constants of Asp, His, Arg, or Ser derivatives were 14, 28, 50, and 53 times lower than that of Ala-Ala-Phe*Nph-Arg-Leu, respectively. (4) pH profile: As shown in Fig. 4 , the pH profile of the k cat /K m values of TPP-I for Ala-Arg-Phe*Nph-Arg-Leu is bell-shaped with an optimum pH of 3.9. In addition, the pK a values were 3.5 and 4.1, respectively. Based on these data, it is suggested that carboxyl or imidazole residues are involved in the catalytic function of TPP-I. DISCUSSION TPP-I (CLN2) is a lysosomal proteinase that participates in protein degradation (10) . A deficiency of this enzyme results in a fatal neurodegenerative disease (Batten's disease) (4) . In order to clarify the biological implications of a TPP-I deficiency, recombinant human TPP-I and its muteins were characterized by molecular and biochemical approaches. Fig. 3 . SDS-PAGE of the purified S280A and E77A muteins. The purified enzymes were analyzed by SDS-PAGE under denaturing condition. After electrophoresis, the proteins were stained with Coomassie Brilliant Blue R-250. Lane 1, S280A; lane 2, E77A; lane 3, wild-type; lane M, molecular weight standards (bovine serum albumin, 66.2 kDa; ovalbumin, 45 kDa; bovine carbonic anhydrase, 31 kDa). Table 2 . Effect of inhibitors on tripeptidyl peptidase activity.
Each inhibitor was incubated with the enzyme at 37°C for 10 min at pH 4.0, and then the remaining activity was measured using AlaAla-Phe-MCA as a substrate. ND, not determined.
Inhibitor
Inhibition (%) 100 µM 1 mM 20 mM AAF-CMK  100  100  ND  acetylpepstatin  0  14  ND  tyrostatin  0  19  ND  Ac-IAF-CHO  30  88  ND  Ac-IPF-CHO  7  38  ND  chymostatin  3 Table 3 . Relative hydrolysis rates of TPP-I, sedolisin, and kumamolisin for P 1 -combinatorial peptide substrates.
Numbers in parentheses are relative activity, %. The recombinant TPP-I showed an optimum pH of 4.0, and was stable in the acidic pH region. The optimum pH of the human brain enzyme was determined to be 3.5, using Gly-Phe-Phe-Leu-amino-trifluoromethyl coumarin as substrate (43) . The bovine brain enzyme was stable at acidic pH but not at neutral or alkaline pH (27) . Thus, the enzymatic properties of the recombinant TPP-I are similar to those reported for naturally occurring enzymes.
The molecular mass of the recombinant TPP-I was estimated to be 46 kDa (Fig. 1, lane 2) . TPP-I is translated as a 66-kDa precursor protein, and then post-translationally glycosylated and processed to a 46-kDa mature enzyme (4, 16) . Based on the DNA sequence, the molecular mass of the mature enzyme is predicted to be 39.7 kDa, with five putative N-glycosylation sites (4, 41) . After deglycosylation of the recombinant TPP-I, the mature enzyme migrated as a single 40-kDa band on SDS-PAGE (Fig. 1, lane 1) , suggesting that the enzyme expressed in pupae is glycosylated by a typical Man 3 -GlcNAc 2 motif, as observed in insect cells (44) .
Lin et al. reported that Ser280 in TPP-I can be labeled by 5 mM DFP (16) . In contrast, recombinant TPP-I is not inhibited by 20 mM AEBSF. Rat spleen and bovine brain enzymes are also insensitive to DFP, PMSF, and AEBSF (26, 27) . In addition, sedolisin and kumamolisin are not inhibited by 10 mM AEBSF. Thus, such chemical modifiers as DFP are not effective for inhibiting sedolisins, even though a serine residue is involved in the catalytic function.
The active site serine residue in serine proteases reacts with the carbonyl of a chloromethyl ketone to give a tetrahedral structure, followed by alkylation of the nitrogen in the imidazole ring of the active site histidine residue (45) . As shown in Table 2 and reported previously (12, 14, 16, 21, 24, 27) , TPP-I was inactivated by AAF-CMK, but the treated enzyme did not recover its activity by dialysis, suggesting that this type of inhibition is irreversible. In addition, TPP-I was inactivated by Ac-IAF-CHO. In kumamolisin, Ac-IAF-CHO was found to bind covalently to the catalytic serine residue (19) . The results described here suggest to us that a Ser residue in TPP-I is also crucial for the catalytic function.
In order to elucidate the identity of the catalytic residues of TPP-I, mutational analysis was carried out. In silkworm pupae, a 46-kDa mature form appeared without acidic activation. This might be due to the cleavage of the precursor protein by endogenous silkworm TPP-I or by other proteinases from infected virus and/or silkworm pupae, as observed in Chinese hamster ovary cells (41, 42) . The muteins S280A and E77A did not show any significant enzymatic activities. Based on the results of inhibition studies and on the sequence similarity with other sedolisins, the involvement of Ser280, Glu77, and Asp81 in TPP-I in the catalytic function of this enzyme is strongly indicated. The involvement of Ser280 and Asp81 has been shown directly before (9, 17) , although Glu77 has not previously been shown experimentally to be one of the catalytic residues in TPP-I. Thus, this study provides the first clear experimental evidence that Glu77 in TPP-I is involved in the catalytic function, most likely as a general base.
TPP-I hydrolyzed Ala-Arg-Phe*Nph-Arg-Leu most effectively among all substrates tested. Kinetic parameters of TPP-I for this peptide were K m = 4.02 µM, k cat = 11.8 s -1 , and k cat /K m = 2.94 µM -1 ·s -1 . The k cat /K m value was 40 times higher than that for Ala-Ala-Phe-MCA, which has been used as a general substrate for TPP-I (21). TPP-I showed lower activities for octa-(S 5 -S 3 ′) and hepta-pep- 
tides (S 4 -S 3 ′) than for hexa-peptides (S 3 -S 3 ′). Sedolisin and kumamolisin did not exhibit any significant activities against Ala-Ala-Phe-MCA. In addition, sedolisin was not inhibited by AAF-CMK. These results suggest that the substrate-binding cleft of TPP-I is shorter than those of other sedolisins, and that it is composed of three nonprime subsites (S 3 -S 1 ) and at least three prime side subsites (S 1 ′-S 3 ′). Homology modeling of the structure of CLN2 based on the experimentally-determined structures of sedolisin and kumamolisin (46) lead to analogous conclusions. TPP-I preferred bulky and hydrophobic amino acid residues at the P 1 position of a substrate, suggesting that the S 1 subsite of TPP-I is large enough to accommodate such bulky amino acid residues, and that it is composed of hydrophobic residues ( Table 3 ). The substrate specificity of authentic TPP-I for natural substrates reported so far is summarized in Table 5 . TPP-I hydrolyzes its known physiological substrate, ATP synthase subunit c, between an Asp3 and a Thr4 residue (P 1 -P 1 ′). TPP-I does not cleave peptides having a Lys at the P 1 position. According to a homology model of TPP-I, it has been predicted that the S 1 pocket of TPP-I has a less polar character than that of sedolisin (46) . The results described above strongly support this prediction.
TPP-I preferentially cleaved peptides having Arg, Ala, or Asp residue at the P 2 position (Table 4) . TPP-I also cleaved natural peptides having Ile, Arg, Val, or Gly at this position (Table 5 ). In contrast, sedolisin and kumamolisin did not exhibit any preference for peptides having such charged amino acid residues at the P 2 position (36, 37, 47) . These results suggest that the electrostatic state of the S 2 pocket in TPP-I is different from those of sedolisin and kumamolisin. The human lysosomal aspartic proteinase, cathepsin D, is involved in the normal degradation of intracellular and endocytosed proteins (48) . Cathepsin D accommodates large hydrophobic residues in the P 2 position of the substrate, but does not prefer such positively charged residues as Lys or Arg in this position (47, 49, 50) .
As shown in Table 4 , TPP-I preferentially hydrolyzed a peptide with a P 3 -Ala substitution. In addition, TPP-I cleaved natural peptides having Asp, Arg or Gly at the P 3 position (Table 5) . TPP-I also hydrolyzed a collagenrelated peptide (23) . In contrast, TPP-I did not cleave natural peptides having Tyr at this position (Table 5) . These results suggest that TPP-I prefers small amino acid residues at the P 3 position. On the other hand, sedolisin and cathepsin D prefer large and hydrophobic residues at this position (36, 47, 49, 50) . Thus, the S 3 subsite of TPP-I may be smaller than those of sedolisin and cathepsin D.
As shown in Table 2 , TPP-I was inhibited by Ac-IAF-CHO. However, the inhibitory activity was weaker than that of AAF-CMK. In contrast, Ac-IAF-CHO showed inhibition for sedolisin and kumamolisin in the micromolar range [K i = 0.6 µM) (18) and (K i = 0.9 µM) (7), respectively]. These results suggest that electrostatic interactions between the amino-terminal group at the P 3 position and a carboxyl group in the S 3 pocket is important for the catalytic reaction. In the homology model of TPP-I, it was predicted that the carboxyl group of Asp132 would extend out into the active site cleft and act as an anchor for the N terminus of the substrate (46) . The experimental result is consistent with that prediction. The pH profile of TPP-I is similar to that of kumamolisin (30) . In kumamolisin, the active site cleft shows a strong negative overall charge (19) . This suggests that the catalytic machinery of TPP-I is identical to that of kumamolisin.
TPP-I is the only member of the family of sedolisins that has been shown to exhibit tripeptidyl peptidase activity. In addition, the P 2 and P 3 
